Antiseizure Medication Choices for FIRES
The evidence provided does not contain specific guidelines for FIRES management, but based on available research, initial treatment should include high-dose benzodiazepines (lorazepam or midazolam), followed by levetiracetam, phenobarbital, and early escalation to ketogenic diet, with immunotherapy (anakinra or tocilizumab) initiated within the first 2-3 weeks when conventional ASMs fail.
Critical Context
The provided guidelines 1 address CAR T-cell therapy complications and simple febrile seizures [@4-9@]—neither of which is FIRES. FIRES is a catastrophic epileptic encephalopathy characterized by super-refractory status epilepticus following a febrile illness, requiring an entirely different treatment paradigm than simple febrile seizures.
Evidence-Based Treatment Algorithm
Acute Phase (Days 1-7)
First-Line ASMs:
- Benzodiazepines: Lorazepam 0.1 mg/kg IV or midazolam continuous infusion
- Levetiracetam: 40-60 mg/kg IV loading dose (up to 4,500 mg), then 30 mg/kg/day divided 2
- Phenobarbital: 20 mg/kg IV loading dose 2
Critical Point: FIRES seizures are notoriously refractory to standard ASMs. The median number of ASMs tried is 6, with minimal efficacy 2.
Early Escalation (Days 7-14)
When seizures persist despite first-line therapy:
Ketogenic Diet: Initiate within the first week—one of the few interventions showing potential efficacy 2. This is not optional in FIRES.
Burst-Suppression Coma: High-dose barbiturates (thiopental or pentobarbital) or midazolam infusions 2
- Major Caveat: Prolonged burst-suppression (>7-10 days) is associated with worse cognitive outcomes 2
- Use the shortest duration possible
Additional ASMs to Consider:
- Perampanel: 2-8 mg/day may reduce barbiturate dependency 3
- Topiramate, valproate, or other broad-spectrum agents
Immunotherapy (Days 10-21)
When conventional ASMs fail (which is typical):
First-Line Immunotherapy:
- Anakinra (IL-1 receptor antagonist): Demonstrated rapid seizure cessation within 24 hours in multiple cases 4, 5, 6
- Initiate early (by day 10-14) to prevent long-term sequelae 5
OR
- Tocilizumab (IL-6 receptor blocker): Associated with SRSE resolution within median 5 days (range 2-12) 7
- Dose: IV infusion per weight-based protocols
- 6/7 patients in one series achieved functional recovery (PCPC ≤2) 7
Second-Line Immunotherapy:
Traditional Immunotherapy (less effective in FIRES):
- IVIG: Minimal evidence of efficacy (2/77 patients responded) 2
- Systemic corticosteroids: Limited benefit 2
- Plasmapheresis: No clear benefit 2
Treatment Sequencing Strategy
Days 1-3: Benzodiazepines + levetiracetam + phenobarbital
Days 3-7: Add ketogenic diet + consider perampanel
Days 7-14: If refractory, initiate burst-suppression coma (minimize duration) + start anakinra or tocilizumab
Days 14-21: If still refractory, add intrathecal dexamethasone to systemic immunotherapy
Beyond Day 21: Consider therapeutic hypothermia, additional experimental therapies
Critical Pitfalls to Avoid
Delaying ketogenic diet: This should be started within the first week, not as a last resort 2
Prolonged burst-suppression: Duration >7-10 days correlates with worse cognitive outcomes 2. Wean as soon as possible.
Waiting too long for immunotherapy: Anakinra and tocilizumab should be initiated by days 10-17, not after weeks of failed conventional therapy 4, 5, 7
Relying on traditional immunotherapy: IVIG and steroids alone have poor efficacy in FIRES 2
Younger age at onset: Associated with worse cognitive outcomes 2
Chronic Phase Management
- 93% develop refractory epilepsy requiring ongoing polytherapy 2
- Only 18% retain normal cognitive function (though most have learning disabilities) 2
- Mortality during acute phase: 11.7% 2
Maintenance ASMs: Typically require 2-4 agents including clobazam, levetiracetam, and others based on seizure semiology 3